Toward the establishment of guidelines for the treatment of steroid-refractory immune-related hepatotoxicity.
作者信息
Yoshio Sachiyo
机构信息
Department of Liver Diseases The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine Ichikawa Japan.
出版信息
JGH Open. 2023 Feb 24;7(2):85-86. doi: 10.1002/jgh3.12880. eCollection 2023 Feb.
Abstract
摘要
相似文献
1
Toward the establishment of guidelines for the treatment of steroid-refractory immune-related hepatotoxicity.迈向制定类固醇难治性免疫相关肝毒性治疗指南
JGH Open. 2023 Feb 24;7(2):85-86. doi: 10.1002/jgh3.12880. eCollection 2023 Feb.
2
The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity.类固醇难治性免疫检查点抑制剂相关肝毒性的现状
Transl Oncol. 2023 Feb;28:101619. doi: 10.1016/j.tranon.2023.101619. Epub 2023 Jan 7.
3
Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events.英夫利昔单抗治疗类固醇难治性免疫相关不良事件的真实世界结局和肝毒性。
Curr Oncol. 2021 Jun 11;28(3):2173-2179. doi: 10.3390/curroncol28030201.
4
Ursodeoxycholic acid and bezafibrate were useful for steroid-refractory, immune-related hepatitis: a case report.熊去氧胆酸和苯扎贝特对类固醇难治性免疫相关性肝炎有效：一例报告。
J Med Case Rep. 2020 Nov 26;14(1):230. doi: 10.1186/s13256-020-02541-3.
5
Evaluation of mycophenolic acid exposure in a patient with immune-related hepatotoxicity caused by nivolumab and ipilimumab therapy for malignant melanoma: a case report.评估纳武单抗和伊匹单抗治疗恶性黑色素瘤引起的免疫相关性肝毒性患者的霉酚酸暴露：病例报告。
Cancer Chemother Pharmacol. 2024 Jun;93(6):633-638. doi: 10.1007/s00280-023-04628-2. Epub 2023 Dec 26.
6
Management and treatment of severe immune-related hepatotoxicity based on clinical and pathological characteristics.基于临床和病理特征的严重免疫相关肝毒性的管理与治疗
Hepatol Int. 2024 Dec;18(6):1770-1780. doi: 10.1007/s12072-024-10688-0. Epub 2024 Jul 2.
7
Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids.英夫利昔单抗治疗类固醇难治性免疫相关性肝炎不会产生肝毒性，并且可能会缩短类固醇治疗时间。
J Immunother Cancer. 2024 Jul 5;12(7):e008074. doi: 10.1136/jitc-2023-008074.
8
Intrathecal Chemotherapy as a Potential Treatment for Steroid-refractory Immune Effector Cell-associated Neurotoxicity Syndrome.鞘内化疗作为治疗类固醇难治性免疫效应细胞相关性神经毒性综合征的一种潜在方法。
Anticancer Res. 2022 Aug;42(8):3853-3856. doi: 10.21873/anticanres.15876.
9
Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management.黑色素瘤免疫检查点抑制剂治疗后的肝毒性：自然病程与管理
Am J Clin Oncol. 2018 Aug;41(8):760-765. doi: 10.1097/COC.0000000000000374.
10
Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology.免疫抑制剂霉酚酸酯用于肿瘤学中由检查点抑制剂诱导的类固醇难治性免疫相关肝炎患者。
Eur J Cancer. 2023 Nov;193:113313. doi: 10.1016/j.ejca.2023.113313. Epub 2023 Aug 26.
本文引用的文献
1
Efficacy and safety of mycophenolate mofetil in treating immune-related hepatitis induced by immune checkpoint inhibitor use: A retrospective study.霉酚酸酯治疗免疫检查点抑制剂所致免疫相关性肝炎的疗效与安全性：一项回顾性研究。
JGH Open. 2023 Feb 13;7(2):87-97. doi: 10.1002/jgh3.12868. eCollection 2023 Feb.
2
The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity.类固醇难治性免疫检查点抑制剂相关肝毒性的现状
Transl Oncol. 2023 Feb;28:101619. doi: 10.1016/j.tranon.2023.101619. Epub 2023 Jan 7.
3
Immune checkpoint inhibitor-related cholangiopathy: Novel clinicopathological description of a multi-centre cohort.免疫检查点抑制剂相关胆管病：多中心队列的新型临床病理描述
Liver Int. 2023 Jan;43(1):147-154. doi: 10.1111/liv.15340. Epub 2022 Jun 23.
4
Re-administration of nivolumab after immune checkpoint inhibitor-induced cholangitis: the first reported case.免疫检查点抑制剂诱发胆管炎后重新使用纳武单抗：首例报告病例
Clin J Gastroenterol. 2022 Apr;15(2):467-474. doi: 10.1007/s12328-022-01590-z. Epub 2022 Feb 24.
5
Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies.免疫检查点抑制剂致晚期恶性肿瘤患者肝损伤的临床病程。
Hepatol Int. 2021 Oct;15(5):1278-1287. doi: 10.1007/s12072-021-10238-y. Epub 2021 Aug 9.
6
A multicenter characterization of hepatitis associated with immune checkpoint inhibitors.免疫检查点抑制剂相关肝炎的多中心特征分析
Oncoimmunology. 2021 Feb 8;10(1):1875639. doi: 10.1080/2162402X.2021.1875639.
7
Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors.肝毒性是限制免疫检查点抑制剂使用增加的一个因素。
JHEP Rep. 2020 Aug 11;2(6):100170. doi: 10.1016/j.jhepr.2020.100170. eCollection 2020 Dec.
8
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.纳武利尤单抗联合伊匹单抗治疗脑转移黑色素瘤。
N Engl J Med. 2018 Aug 23;379(8):722-730. doi: 10.1056/NEJMoa1805453.
9
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.使用免疫检查点抑制剂的癌症免疫疗法诱导的肝损伤的特征。
J Hepatol. 2018 Jun;68(6):1181-1190. doi: 10.1016/j.jhep.2018.01.033. Epub 2018 Feb 8.
10
Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer.尼伏单抗相关胆管炎在非小细胞肺癌患者的影像学和临床病理特征。
Invest New Drugs. 2017 Aug;35(4):529-536. doi: 10.1007/s10637-017-0453-0. Epub 2017 Mar 20.
Zotero 插件